Novo Nordisk Launches Once-Weekly Basal Insulin Awiqli in India for Diabetes Treatment
Danish pharmaceutical company Novo Nordisk has launched Awiqli (insulin icodec), the world's first once-weekly basal insulin, in India. Designed for adults with Type 1 and Type 2 diabetes, Awiqli reduces insulin injections from 365 to 52 annually, aiming to ease injection-related anxiety and improve adherence. Priced at approximately Rs 2,611 for a 700-unit pen, it is positioned as a cost-effective alternative to daily basal insulins. The launch addresses India's significant diabetes burden and delayed insulin initiation due to fear and cost concerns.
First-hand measurement across 15 sources
We measured how 15 outlets covered this story. Coverage leans balanced overall (Left 0%, Centre 100%, Right 0%). Overall sentiment is positive (75/100). Lens Score 30/100.
Outlets measured: economictimes, hindustantimes, hindustantimes, thefinancialexpress, theprint, wion, indianexpress, thehindu, and 7 more. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
All 15 outlets scored close to centre on political lean. The real divergence here is in emphasis, not lean — compare the headlines below to see how each outlet chose to frame the same facts.
Sentiment was consistent across outlets (70–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 9 Jul, 07:45 am. Other outlets followed.